

August 28, 1957

H. R. Hanmer

Mr. Stephen R. Winslow

Dr. Paul S. Larson (Professor of Pharmacology at the Medical College of Virginia), Dr. Charles C. Clayton (Assistant Professor of Biochemistry, M.C.V.) and Ed Harlow visited the Detroit Institute of Scientific Research in December, 1953, to discuss with Dr. W. T. Simpson (Director of the Institute), Mr. Sheridan and Dr. Gordon Scott (Dean of Medicine at Wayne University) our possible support of research on the use of tetrahydroxyquinone and related compounds in the treatment of cancer and other diseases. Dr. Simpson and Dr. Scott were reluctant to make any formal request for funds in support of such research at the Institute until the status of Mr. Winslow's connection with Mr. Sheridan's work was clarified. Their reservations were concerned primarily with the fact that Mr. Winslow might have some legal reason to suppose that he would have the prior right to manufacture any useful products that could stem from this investigation. Dr. Simpson felt that unless this question could be resolved, the Institute was placed in a completely untenable position and would not agree to any arrangement that might lead to restricted commercial profit by any individual or company. In fact, Dr. Simpson stated categorically that if this matter could not be cleared up, his only alternative would be to abandon all further work along these lines.

On January 5, Dr. Simpson wrote to Mr. Harlow stating that it had not yet been possible to find a satisfactory solution to the problem mentioned above. The last week in March of 1954 Dr. Scott and Dr. Simpson visited us in Richmond at which time we discussed the subject of cancer research financing in general. No resolution of the aforementioned problem had been forthcoming at this point. We have had no further communication from Dr. Simpson since that time and hence believe he was unable to find a satisfactory solution.

Our latest contact with Mr. Winslow was in late July, 1954, when he visited me. On August 2, 1954, I received a communication from Dr. W. A. Fansler, who wrote at the request of Mr. David Winslow regarding his use of a material called KC-49 in the treatment of cancer patients. KC-49 is a mixture of polyhydroxy cyclic compounds related to inositol, originally prepared by Mr. Sheridan and which was used unsuccessfully in an early attempt at the Detroit Institute to cause regression of malignant tissue.

Information on Dr. Frank B. Queen, taken from American Men of Science, 9th Edition, Volume II, is appended. Apparently Dr. Queen is an accomplished scientist. We will try to confirm Winslow's report on Dr. Queen's research activities.

ESH:sacs

Attachment